Page 29 - ARNM-3-2

Advances in Radiotherapy
& Nuclear Medicine Lipid-radiotherapy crosstalk in cancer

rescues cell viability post-radiotherapy, demonstrating peer-review process conducted for this paper, directly or
a markedly superior effect to other regulated cell death indirectly. Separately, the other author declares no known
inhibitors. Notably, the ferroptotic response was shown competing financial interests or personal relationships that
to correlate directly with both radiation dosage and could have influenced the work reported in this paper.
fractionation schemes, underscoring its dynamic nature in
therapeutic contexts. 34 Author contributions

5. Conclusion and prospect Conceptualization: Jiahua Lyu
Writing – original draft: Jinxia Wu
Blood lipids represent a modifiable factor in cancer treatment, Writing – review & editing: Jiahua Lyu
potentially enhancing radiotherapy efficacy through dietary
and pharmacological interventions. Studies have shown Ethics approval and consent to participate
that oral omega-3 polyunsaturated fatty acids can improve Not applicable.
the nutritional status and regulate inflammation markers in
lung cancer patients undergoing radiotherapy. Emerging Consent for publication
35
evidence suggests that omega-3 polyunsaturated fatty acids
may improve nutritional status and modulate inflammation in Not applicable.
36
lung cancer patients undergoing radiotherapy. Furthermore, Availability of data
some cohort studies have demonstrated that statins can be
used in radiotherapy for nasopharyngeal carcinoma, head- Not applicable.
and-neck tumors, and chest tumors, reducing the risk of
vascular complications, such as stroke and transient ischemic References
attacks in patients. 37-39 However, the exact mechanisms of 1. De Martel C, Georges D, Bray F, Ferlay J, Clifford GM.
how diet and medication regulate blood lipids concerning Global burden of cancer attributable to infections in 2018:
radiotherapy remain unclear. More extensive, multicenter, A worldwide incidence analysis. Lancet Glob Health.
randomized controlled trials are needed in the future. Based 2020;8(2):e180-e190.
on the current research, we may attempt to optimize dietary doi: 10.1016/S2214-109X(19)30488-7
plans by combining patients’ blood lipid levels with tumor 2. Zhang X, Yang L, Liu S, et al. Interpretation on the report of
types to better control lipid levels.
global cancer statistics 2022. Zhonghua Zhong Liu Za Zhi.
In this review, we discussed the mutual influence 2024;46(7):710-721.
between tumor radiotherapy and blood lipid levels and doi: 10.3760/cma.j.cn112152-20240416-00152
how regulating blood lipids through diet and medication
can enhance the efficacy of radiotherapy. Although 3. Kumar V, Singh A, Sidhu DS, Panag KM. A comparitive
controlling blood lipids has shown specific synergistic study to evaluate the role of serum lipid levels in aetiology of
effects in radiotherapy, more extensive clinical studies are carcinoma breast. J Clin Diagn Res. 2015;9:PC01-PC03.
still needed to provide evidence for clinical guidelines and doi: 10.7860/JCDR/2015/12273.5563
expert consensus. The growth characteristics of different 4. Yilin Yu, Yu J, Ge S, Su Y, Fan X. Novel insight into
tumor types vary, and their lipid demands also differ. metabolic reprogrammming in cancer radioresistance: A
Therefore, controlling blood lipids in tumor patients promising therapeutic target in radiotherapy. Int J Biol Sci.
should involve personalized management based on the 2023;19(3):811-828.
patient’s baseline conditions and tumor type. doi: 10.7150/ijbs.79928

Acknowledgments 5. Arboleda LP, De Carvalho GB, Santos-Silva AR, et al.
Squamous cell carcinoma of the oral cavity, oropharynx, and
None. larynx: A scoping review of treatment guidelines worldwide.
Funding Cancers (Basel). 2023;15(17):4405.
doi: 10.3390/cancers15174405
This work was supported by the Natural Science Foundation
of Sichuan Province (Grant No. 2023NSFSC0712). 6. Matos LL, Kowalski LP, Chaves ALF, et al. Latin American
consensus on the treatment of head and neck cancer. JCO
Conflict of interest Glob Oncol. 2024;10:e2300343.

Jiahua Lyu is an Editorial Board Member of this journal doi: 10.1200/GO.23.00343
but was not in any way involved in the editorial and 7. Jelonek K, Krzywon A, Jablonska P, et al. Systemic effects of

Volume 3 Issue 2 (2025) 21 doi: 10.36922/ARNM025070006